TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04841161

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Balance function, gait ability, weight- distribution and weight-shifting
Description: Healthy adults and stroke patients accepted two measurements within a week. Balance function, gait ability, weight- distribution and weight-shifting during sit-to-stand, quite standing, and weight-shifting toward the forward foot.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance function, gait ability, weight- distribution and weight-shifting
Description: Healthy adults and stroke patients accepted two measurements within a week. Balance function, gait ability, weight- distribution and weight-shifting during sit-to-stand, quite standing, and weight-shifting toward the forward foot.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight- distribution and weight-shifting training program
Description: The stroke patients received a weight-shifting training program , 30 minutes/time, 2-5 days a week for 2-3 weeks(8 sessions). After training, they accepted a post-test within a week.
Study: NCT03644914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10-week Reading Program
Description: Intervention sessions will be carried out during the school day in a private school room. In each session, the investigator will work with the child individually to help him or her read better. Intervention will incorporate word recognition and phonetic decoding of words established as meeting 1st grade essential literacy standards. Learning techniques will involve games, play, movement, music, and breaks (i.e., the child is able to move about and associate words with color, video, and music. Three 5-minute breaks will be integrated into each 1-hour session to allow the child time to rest and process learned material). Intervention will also use each child's personal interests as a context around which sight words will be learned.
Study: NCT01155466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant 2 mg tablet
Description: one 2 mg tablet orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant 5 mg tablet
Description: one 5 mg tablet orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant 10 mg tablet
Description: one 10 mg tablet orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Preladenant Tablet
Description: one tablet orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Preladenant Tablet
Description: one tablet orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline 1 mg capsule
Description: one 1 mg capsule orally in AM

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Rasagiline capsule
Description: one capsule orally in AM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Rasagiline capsule
Description: one capsule orally in AM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Rasagiline capsule
Description: one capsule orally in AM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Rasagiline capsule
Description: one capsule orally in AM
Study: NCT00590824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hu14.18-IL2
Description: 6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course followed by surgery and up to 2 additional courses of hu14.18-IL2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hu14.18-IL2
Description: Surgery followed by 3 courses of 6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course
Study: NCT00869245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OU - Cardiac MRI
Description: During ED evaluation, patients are randomized to cardiac MRI or conventional care testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OU - Conventional Care Testing
Description: Patients in the conventional testing arm will undergo testing as determined by their treating physician.
Study: NCT02443194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duloxetine
Description: after randomization the patient will receive cymbalta/ placebo for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: after randomization the patient will receive cymbalta/ placebo for 3 months
Study: NCT00380029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be given at a dose of 150 mg per day for 4 weeks before undergoing planned radical cystectomy. In addition, patients will continue on erlotinib daily at a dose of 150 mg per day (qd dosing) for up to 2 years after surgery (beginning within 12 weeks of surgery) or until evidence of disease recurrence or progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Will occur 4 weeks prior to dosing with erlotinib
Study: NCT04701671

Intervention type: BEHAVIORAL
Intervention: Observational (not including MRI scanning)
Description: Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.

Intervention type: BEHAVIORAL
Intervention: Observational (not including MRI scanning)
Description: Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.

Intervention type: BEHAVIORAL
Intervention: Observational (not including MRI scanning)
Description: Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.

Intervention type: BEHAVIORAL
Intervention: Observational (including MRI scanning)
Description: Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, fMRI imaging, and a semi-structured interview.

Intervention type: BEHAVIORAL
Intervention: Observational (including MRI scanning)
Description: Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, fMRI imaging, and a semi-structured interview.

Intervention type: BEHAVIORAL
Intervention: Observational (including MRI scanning)
Description: Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, fMRI imaging, and a semi-structured interview.
Study: NCT03608137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships
Description: To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships
Description: To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.
Study: NCT03094364

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaming CI Therapy
Description: Intensive remote (via video game) therapy for upper extremity hemiparesis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaming CI Therapy
Description: Intensive remote (via video game) therapy for upper extremity hemiparesis.
Study: NCT03634566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylecysteine
Description: N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ringer acetate continuous infusion at the same rate for 2 days.
Study: NCT01344538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger Root Extract (Pure Encapsulations)
Description: 2.0 g per day (10:1 extract)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: 2.0 g per day
Study: NCT01267331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow mononuclear cells injection
Description: Participants will receive direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo intramyocardial injection
Description: Participants will receive between 10 and 15 placebo injections that consist of saline and 5% human serum albumin during CABG.
Study: NCT03144193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical anti-aging cosmetic cream
Description: Topical anti-aging cosmetic cream
Study: NCT01693562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
Study: NCT03144193

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical anti-aging cosmetic cream
Description: Topical anti-aging cosmetic cream
Study: NCT02442765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03566615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAP-straight
Description: This study is to detect any differences in the detection rate of adenomas using straight caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAP-daisy
Description: This study is to detect any differences in the detection rate of adenomas using daisy caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water
Description: using water instead of traditional air insufflation to help insertion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water
Description: using water instead of traditional air insufflation to help insertion
Study: NCT03226756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Nivolumab 3 mg/kg, every 2 weeks
Study: NCT02850263

Intervention type: DRUG
Intervention: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: Anti-VEGF exposure is defined as treatment with intravitreal aflibercept for the treatment of DMO by the patient.according to the prescribing physician.

Intervention type: DRUG
Intervention: Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)
Description: Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
Study: NCT01866501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EZ-IO
Study: NCT02336802

Intervention type: BEHAVIORAL
Intervention: Avoidance experiment
Description: Participants complete an avoidance task
Study: NCT04018300

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 65 mg Fe as ferrous sulfate
Study: NCT02850263

Intervention type: DRUG
Intervention: Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)
Description: Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
Study: NCT03163693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: receive dexmedetomidine 0.5 μg/kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: receive equal volume of normal saline
Study: NCT01395121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatment
Study: NCT00665756

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: second Trabeculectomy
Description: second trabeculectomy with mitomycin-c

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Implant
Description: Ahmed silicone drainage device
Study: NCT04734223

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging Findings in Patients With COVID-19
Description: MR and BT Imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging Findings in Patients With COVID-19
Description: MR and BT Imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging Findings in Patients With COVID-19
Description: MR and BT Imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging Findings in Patients With COVID-19
Description: MR and BT Imaging
Study: NCT03649711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: Ticagrelor Pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90mg
Description: Ticagrelor Pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: Clopidogrel Pill and a matching placebo to conceal frequency

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: Aspirin Pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Aspirin Pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: Aspirin Pill
Study: NCT00301535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBOC-201 (hemoglobin glutamer-250 bovine)
Description: HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
Study: NCT02174523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40mg lurasidone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01340937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V419
Description: V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V419
Description: V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.
Study: NCT04018300

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspiron
Description: 65 mg Fe as iron-enriched koji culture, called AspironTM

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains maltodextrin.
Study: NCT02697695

Intervention type: OTHER
Intervention: Laboratory Examination
Description: Laboratory Examination before, 1 month, 3 month, 6 month and up to 12 month after LSK, LRNYGB, LOLGB

Intervention type: OTHER
Intervention: Laboratory Examination
Description: Laboratory Examination before, 1 month, 3 month, 6 month and up to 12 month after LSK, LRNYGB, LOLGB

Intervention type: OTHER
Intervention: Laboratory Examination
Description: Laboratory Examination before, 1 month, 3 month, 6 month and up to 12 month after LSK, LRNYGB, LOLGB
Study: NCT01340937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V419
Description: V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PENTACEL™
Description: PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENTACEL™
Description: PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENTACEL™
Description: PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENTACEL™
Description: PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13™
Description: Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13™
Description: Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13™
Description: Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq™
Description: RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™
Description: RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™
Description: RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™
Description: RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombivax HB vaccine
Description: Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
Study: NCT02055534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the oncologists

Intervention type: OTHER
Group type: OTHER
Intervention: General dietary advices
Description: General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the oncologists
Study: NCT01839240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04920591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: doll treatment
Description: The doll used in the study is the empathy doll; these dolls are designed to obtain an optimal interaction with patients and to arouse empathy.
Study: NCT00277888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral route for hemodialysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jugular route for hemodialysis
Study: NCT01808053

Intervention type: DEVICE
Intervention: BodyGuardian remote health monitoring system
Description: The remote health management system connects personal health sensors with secure mobile communication devices. It is also able to give immediate feedback to the user. The solution is a multi-tiered mobile health platform. The front-end includes an adhesive snap-strip body sensor (BodyGuardian) that can measure HR, ECG, respiration rate (RR), and activity which is FDA approved for detection of non-lethal cardiac arrhythmias. It can wirelessly communicate with off-body sensors such as a BP cuff and scale to incorporate BP and weight data based on automated algorithms and can solicit symptoms from the user. It can also be used as an event recorder inputting symptoms and recording simultaneous physiologic data.
Study: NCT03867604

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Injection to the subcutaneous layer at upper trapezium level

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia injection
Description: Injection to the fascia below upper trapezium muscle
Study: NCT02442765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03446183

Intervention type: BEHAVIORAL
Intervention: Smoking cessation workshops
Description: All the participants took part in smoking cessation workshops. The comparison of metabolic aspects was made between the smokers and non-smokers